LGD-4033 and Proviron Interaction

Avoid
Mechanism-based 64% confidence

LGD-4033 and Proviron have a potentially harmful interaction with 64% confidence. Both LGD-4033 and Proviron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Proviron

DHT Derivative | Mood, Libido & Muscle Hardening

Proviron exerts its effects primarily through direct binding to the androgen receptor (AR) as a potent DHT analogue. However, its most therapeutically relevant mechanism is its exceptionally high binding affinity for sex hormone-binding globulin (SHBG).

Half-life: ~12 hours Typical dose: 25-75 mg/day anabolic, sexual health
androgen receptoraromataseepo receptorshbg androgenicaromatase inhibitorcarcinogenic riskhepatotoxic
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate

Shared Safety Flags

2x 2 androgenic compounds (LGD-4033, Proviron). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds share the carcinogenic-risk safety flag (LGD-4033, Proviron). Monitor accordingly.
2x 2 hepatotoxic compounds (LGD-4033, Proviron). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (LGD-4033, Proviron). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (LGD-4033, Proviron). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (LGD-4033, Proviron). Monitor accordingly.

Frequently Asked Questions

Can I take LGD-4033 with Proviron?

Combining LGD-4033 with Proviron is not recommended. Both LGD-4033 and Proviron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and Proviron safe together?

This combination carries significant risk. Both LGD-4033 and Proviron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and Proviron?

Both LGD-4033 and Proviron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Proviron?

LGD-4033 has a half-life of ~24-36 hours and Proviron has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LGD-4033 vs Proviron

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.